Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)
|
November 8, 2017
Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia
Don A Delker, Austin C Wood, Angela K Snow, et al.
Frontiers in Oncology
|
June 9, 2023
Current chemoprevention approaches in Lynch syndrome and Familial adenomatous polyposis: a global clinical practice survey
Kathryn A Mraz, Rachel Hodan, Linda Rodgers-Fouche, et al.
JNCI Cancer Spectrum
|
January 15, 2025
Rethinking the rise of early-onset gastrointestinal cancers: a call to action
Benjamin A Weinberg, Caitlin C Murphy, David R Freyer, et al.
JAMA
|
March 23, 2016
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial
N Jewel Samadder, Deborah W Neklason, Kenneth M Boucher, et al.
Gut
|
May 31, 2022
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis
N Jewel Samadder, Nathan Foster, Ryan P McMurray, et al.
Nature Cell Biology
|
August 17, 2017
Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism
John C Schell, Dona R Wisidagama, Claire Bensard, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 6, 2020
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020
Dawn Provenzale, Reid M Ness, Xavier Llor, et al.
The New England Journal of Medicine
|
September 9, 2020
Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis
Carol A Burke, Evelien Dekker, Patrick Lynch, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2019
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019
Samir Gupta, Dawn Provenzale, Xavier Llor, et al.
Gut
|
July 10, 2020
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Laura Reyes-Uribe, Wenhui Wu, Ozkan Gelincik, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
Cancer Prevention Research (Philadelphia, Pa.)
|
November 8, 2017
Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia
Don A Delker, Austin C Wood, Angela K Snow, et al.
Frontiers in Oncology
|
June 9, 2023
Current chemoprevention approaches in Lynch syndrome and Familial adenomatous polyposis: a global clinical practice survey
Kathryn A Mraz, Rachel Hodan, Linda Rodgers-Fouche, et al.
JNCI Cancer Spectrum
|
January 15, 2025
Rethinking the rise of early-onset gastrointestinal cancers: a call to action
Benjamin A Weinberg, Caitlin C Murphy, David R Freyer, et al.
JAMA
|
March 23, 2016
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial
N Jewel Samadder, Deborah W Neklason, Kenneth M Boucher, et al.
Gut
|
May 31, 2022
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis
N Jewel Samadder, Nathan Foster, Ryan P McMurray, et al.
Nature Cell Biology
|
August 17, 2017
Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism
John C Schell, Dona R Wisidagama, Claire Bensard, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 6, 2020
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020
Dawn Provenzale, Reid M Ness, Xavier Llor, et al.
The New England Journal of Medicine
|
September 9, 2020
Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis
Carol A Burke, Evelien Dekker, Patrick Lynch, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2019
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019
Samir Gupta, Dawn Provenzale, Xavier Llor, et al.
Gut
|
July 10, 2020
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Laura Reyes-Uribe, Wenhui Wu, Ozkan Gelincik, et al.
Page
of 6